John Edward Tellew

Title: John Edward Tellew: Innovator in CRF Receptor Antagonists

Introduction

John Edward Tellew is a notable inventor based in San Diego, CA. He has made significant contributions to the field of pharmacology, particularly in the development of corticotropin-releasing factor (CRF) receptor antagonists. With a total of 2 patents, Tellew's work has the potential to impact the treatment of various disorders.

Latest Patents

Tellew's latest patents include innovative compounds known as Pyrazolo[1,5-alpha]pyrimidinyl derivatives. These compounds are designed to function as CRF receptor antagonists, which may be useful in treating disorders characterized by hypersecretion of CRF in mammals. The patents detail the structure of these antagonists and their pharmaceutically acceptable salts, esters, solvates, stereoisomers, and prodrugs. Additionally, Tellew's patents disclose compositions containing these CRF receptor antagonists in combination with suitable pharmaceutical carriers, along with methods for their use.

Career Highlights

Throughout his career, Tellew has worked with prominent companies in the biotechnology sector, including Neurocrine Biosciences, Inc. and Sb Cork. His experience in these organizations has allowed him to refine his expertise in drug development and innovation.

Collaborations

Tellew has collaborated with several professionals in his field, including Marion Lanier and John Patrick Williams. These collaborations have likely contributed to the advancement of his research and the successful development of his patents.

Conclusion

John Edward Tellew is a distinguished inventor whose work on CRF receptor antagonists holds promise for the treatment of various medical conditions. His contributions to pharmacology and collaboration with industry professionals underscore his impact in the field.